Lung and Pleural Cancers

Chapter

Abstract

Lung cancer is the most frequently diagnosed cancer in the world, and the prevalence of lung cancer is increasing globally (Smith RA, Glynn TJ. Epidemiology of lung cancer. Radiol Clin North Am 2000;38:453–70). It is the leading cause of death from cancer, and the death occurs at a higher frequency in men than in women in most parts of the world (Magrath I, Litvak J. Cancer in developing countries: opportunity and challenge. J Natl Cancer Inst 1993;85:862–73). There were 169,400 estimated new cases of lung cancer in 2002. Lung cancer claims approximately 150,900 lives each year in the United States, and 20,000 more women died of lung cancer than breast cancer in 2002 (Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47). The survival rate is poor, largely because lung cancer is usually diagnosed at an advanced stage. The overall 5-year survival of patients with lung cancer is approximately 14% and has remained unchanged over several decades despite aggressive treatment protocols (Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47). Therefore, new diagnostic and treatment strategies are needed if an impact is to be made on the survival of patients with lung cancer. A cure may be achieved by surgery, which is feasible only in patients who present at an early stage. However, even in the early stage, approximately 75% of patients will die of recurrent disease (Smith RA, Glynn TJ. Epidemiology of lung cancer. Radiol Clin North Am 2000;38:453–70, Bepler G. Lung cancer epidemiology and genetics. J Thorac Imaging 1999;14:228–34). Lung cancer is rare before the age of 40 years, after which age-specific rates rise sharply. The ages with the greatest incidence are between 65 and 79 years (Smith RA, Glynn TJ. Epidemiology of lung cancer. Radiol Clin North Am 2000;38:453–70).

Keywords

Adenocarcinoma Arsenic Pneumonia Tuberculosis Radionuclide 

References

  1. 1.
    Smith RA, Glynn TJ. Epidemiology of lung cancer. Radiol Clin North Am. 2000;38:453–70.PubMedCrossRefGoogle Scholar
  2. 2.
    Magrath I, Litvak J. Cancer in developing countries: opportunity and challenge. J Natl Cancer Inst. 1993;85:862–73.PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23–47.PubMedCrossRefGoogle Scholar
  4. 4.
    Bepler G. Lung cancer epidemiology and genetics. J Thorac Imaging. 1999;14:228–34.PubMedCrossRefGoogle Scholar
  5. 5.
    Quint LE, Francis IR. Radiologic staging of lung cancer. J Thorac Imaging. 1999;14:235–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Mack MJ, Hazelrigg JR, Lartdreneau RJ, Acuft TE. Thoracoscopy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann Thorac Surg. 1993;56:825–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Smith TAD. FDG uptake, tumor characteristics, and response to therapy: a review. Nucl Med Commun. 1998;19:97–105.PubMedCrossRefGoogle Scholar
  8. 8.
    Ginsberg RS, Vokes EE, Rosenzweig K. Non-small cell cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 6th ed. Philadelphia: Lippincott-Raven; 2002. p. 925–82.Google Scholar
  9. 9.
    Sone S, Sakai F, Takashima S, et al. Factors affecting the radiologic appearance of peripheral bronchogenic carcinomas. J Thorac Imaging. 1997;12:159–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Mountain C, Libshitz HI, Hermes KE. Lung cancer: a handbook for staging and imaging. Houston: University of Texas M.D. Anderson Cancer Center; 1992.Google Scholar
  11. 11.
    Yankelevitz DF, Henschke CI. Small solitary pulmonary nodules. Radiol Clin North Am. 2000;38:471–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Romney BM, Austin JH. Plain film evaluation of carcinoma of the lung. Semin Roetgenol. 1990;25:45–63.CrossRefGoogle Scholar
  13. 13.
    Bouchard EW, Falken S, Molina PL. Lung cancer: a radiologic overview. Appl Radiol. 2007;7–19.Google Scholar
  14. 14.
    Swensen SJ, Morin RL, Schueller B, et al. Solitary pulmonary nodule: CT evaluation of enhancement with iodinated contrast material: a preliminary report. Radiology. 1992;182:343–7.PubMedGoogle Scholar
  15. 15.
    Schuster MR, Scanlan KA. “CT angiogram sign” establishing the differential diagnosis. Radiology. 1991;178:90–5.Google Scholar
  16. 16.
    Park BJ, Louie D, Altorki N. Staging and the surgical management of lung cancer. Radiol Clin North Am. 2000;38:545–58.PubMedCrossRefGoogle Scholar
  17. 17.
    Obuchowski NA, Graham RJ, Baker ME, Powell KA. Ten criteria for effective screening: their application to multislice CT screening for pulmonary and colorectal cancers. AJR Am J Roentgeno. 2001;176:1357–62.Google Scholar
  18. 18.
    Henschke CI, Yartkelevitz DF. Screening for lung cancer. J Thorac Imaging. 2000;15:21–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Hatabu H, Syock KW, Sher S, et al. Magnetic resonance imaging of the thorax. Radiol Clin North Am. 2000;38:593–616.PubMedCrossRefGoogle Scholar
  20. 20.
    Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Coleman RE. PET in lung cancer. J Nucl Med. 1999;40:814–20.PubMedGoogle Scholar
  22. 22.
    Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med. 1995;36:883–7.PubMedGoogle Scholar
  23. 23.
    Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta analysis. JAMA. 2001;285:914–24.PubMedCrossRefGoogle Scholar
  24. 24.
    Gambhir SS, Czernim J, Schwimmer J, et al. A tabulated summary of the FDG-PET literature. J Nucl Med. 2001;42(Suppl):1S–92.PubMedGoogle Scholar
  25. 25.
    Graeber GM, Gupta NC, Murray GF. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg. 1999;117:719–27.PubMedCrossRefGoogle Scholar
  26. 26.
    Pieterman RM, VanPutten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med. 2000;343:254–61.PubMedCrossRefGoogle Scholar
  27. 27.
    Hicks RJ, Kalff V, MacManus MP, et al. 18F-FDG-PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596–604.PubMedGoogle Scholar
  28. 28.
    Kernstine KH, McLaughlin KA, Menda Y, et al. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? Ann Thorac Surg. 2002;73:394–402.PubMedCrossRefGoogle Scholar
  29. 29.
    Patz Jr EF, Lowe VJ, Hoffman JM, et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology. 1994;191:379–82.PubMedGoogle Scholar
  30. 30.
    Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med. 1995;36:788–93.PubMedGoogle Scholar
  31. 31.
    Kamel EM, Goerres GW, Burger C, von Schulthess GK, Steinert HC. Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion- report of six cases. Radiology. 2002;224(1):153–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Kim B-T, Lee KS, Shim SS, et al. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT- a prospective study. Radiology. 2006;24(2):501–9.CrossRefGoogle Scholar
  33. 33.
    Brink C, Schumacher T, Mix M, et al. Impact of F-18 FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31(12):1614–20.PubMedCrossRefGoogle Scholar
  34. 34.
    Diederich S, Semik M, Lentschig MG, et al. Helical CT of pulmonary nodules in patients with extrathoracic malignancy: CT-surgical correlation. AJR Am J Roentgeno. 1999;172(2):353–60.Google Scholar
  35. 35.
    Schirmeister H, Kuhn T, Guhlmann A, et al. F-18 FDG PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med Mol Imaging. 2001;28(3):351–8.CrossRefGoogle Scholar
  36. 36.
    Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 1999;40(8):1241–5.PubMedGoogle Scholar
  37. 37.
    Steinert HC, Santos DMM, Burger C, Stahel R. Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging. Lung Cancer. 2005;49(Suppl 1):S33–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Departments of Nuclear Medicine and Diagnostic RadiologyThe University of Texas MD Anderson Cancer Center and Medical SchoolHoustonUSA
  2. 2.Graduate School of Convergence Science and TechnologySeoul National UniversitySeoulSouth Korea

Personalised recommendations